

Supplemental Table 1. Potential function of the five selected SNPs in *XPG* gene as predicted by SNPinfo

(<http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm>) software

rs	Chr	Allele	Position ^a	Location	TFBS	Splicing (ESE or ESS)	miRNA (miRanda)	miRNA (Sanger)	Reg Potential	Conservation	Nearby Gene	Distance (bp)	Allele	Asian	CHB
rs2094258	13	C/T	102294760	5' near gene	Y	--	--	--	0	0.001	BIVM ERCC5	-2878 -1415	C	0.627	0.661
rs751402	13	C/T	102296199	5' UTR	Y	Y	--	--	0.25613	0	ERCC5	24 30147	C	0.591	0.619
rs2296147	13	T/C	102296376	5' UTR	Y	--	--	--	0.175993	0	ERCC5	201 29970	T	0.838	0.768
rs1047768	13	T/C	102302518	exon	--	Y	--	--	0.24405	0.914	ERCC5	6343 23828	T	0.778	0.720
rs873601	13	G/A	102326338	3' UTR	--	Y	Y	Y	0	0.005	ERCC5	30163 8	G	0.517	0.464

^a The position is based on HapMap Data Rel 27 Phase II+III, Feb09, on NCBI B36 assembly, dbSNP b126.

SNP, single nucleotide polymorphism; XPG, xeroderma pigmentosum group G; TFBS, transcription factor binding site; ESE, exon splicing enhancer; ESS, exon splicing silencer; bp, base pair; CHB, Han Chinese in Beijing, China; UTR, untranslated region; ERCC5, excision repair cross-complementation group 5.

Supplemental Table 2. *XPG* mRNA expression by the genotypes of SNPs, using genotype data from the HapMap and mRNA expression data were from SNPexp^a

Population	rs2094258 C>T					rs751402 C>T					rs873601 G>A				
	genotypes	No.	Mean ± SD	<i>P</i> ^b	<i>P</i> _{trend} ^c	genotypes	No.	Mean ± SD	<i>P</i> ^b	<i>P</i> _{trend} ^c	genotypes	No.	Mean ± SD	<i>P</i> ^b	<i>P</i> _{trend} ^c
CHB	CC	19	9.77 ± 0.21		0.027	CC	15	9.90 ± 0.19		0.064	GG	8	9.96 ± 0.15		0.003
	CT	23	9.90 ± 0.21	0.044		CT	22	9.86 ± 0.21	0.596		AG	26	9.88 ± 0.19	0.314	
	TT	3	9.96 ± 0.16	0.142		TT	8	9.71 ± 0.24	0.055		AA	11	9.69 ± 0.23	0.011	
	Dominant	26	9.91 ± 0.20	0.027		Dominant	30	9.82 ± 0.22	0.264		Dominant	37	9.82 ± 0.22	0.112	
	Recessive	42	9.84 ± 0.21	0.349		Recessive	37	9.88 ± 0.28	0.046		Recessive	34	9.90 ± 0.18	0.003	
Asian	CC	30	9.72 ± 0.20		0.186	CC	30	9.79 ± 0.21		0.196	GG	20	9.77 ± 0.25		0.106
	CT	52	9.77 ± 0.23	0.292		CT	47	9.76 ± 0.22	0.537		AG	49	9.80 ± 0.21	0.682	
	TT	8	9.82 ± 0.24	0.246		TT	13	9.69 ± 0.23	0.188		AA	21	9.67 ± 0.20	0.132	
	Dominant	60	9.78 ± 0.23	0.230		Dominant	60	9.75 ± 0.22	0.046		Dominant	70	9.76 ± 0.21	0.776	
	Recessive	82	9.76 ± 0.22	0.423		Recessive	77	9.77 ± 0.22	0.233		Recessive	69	9.79 ± 0.22	0.021	
All ^d	CC	147	9.74 ± 0.19		0.074	CC	119	9.78 ± 0.22		0.030	GG	83	9.81 ± 0.22		0.001
	CT	108	9.78 ± 0.23	0.121		CT	119	9.77 ± 0.21	0.693		AG	114	9.77 ± 0.20	0.301	
	TT	15	9.81 ± 0.25	0.212		TT	32	9.67 ± 0.21	0.010		AA	64	9.69 ± 0.20	0.002	
	Dominant	123	9.79 ± 0.23	0.084		Dominant	151	9.75 ± 0.21	0.220		Dominant	178	9.74 ± 0.20	0.029	
	Recessive	255	9.76 ± 0.21	0.387		Recessive	238	9.77 ± 0.21	0.008		Recessive	197	9.79 ± 0.21	0.001	

^a Genotyping data for *XPG* by genotypes were obtained from the HapMap phase II release 23 data (<http://hapmap.ncbi.nlm.nih.gov/>) from EBV-transformed lymphoblastoid cell lines from 270 individuals and mRNA expression data were from SNPexp (<http://app3.titan.uio.no/biotools/help.php?app5snpexp>) also from the 270 individuals.

^b Calculated by two-side Student's *t* test within the stratum.

^c Trend test of *XPG* mRNA expression among three genotypes by a general linear model.

^d There were missing data for the genotypes were not available for nine CEU subjects.